Navigation Links
Norovirus, AIDS vaccine and Hepatitis Virus

ch 2005 issue of the Journal of Virology.

Hepatitis B (HBV) and C (HCV) are viruses that infect the liver, and in some cases can cause liver failure requiring a transplant for survival. The protein interferon, produced by animal cells when they are invaded by viruses, is released into the bloodstream or intercellular fluid to induce healthy cells to manufacture an enzyme that counters the infection. One class of interferons (alpha) is used to treat chronic infection with HBV and HCV. There is a vaccine available to prevent the spread of HBV but not HCV.

In the study, a new class of interferons, interferon lambda, was tested for its ability to inhibit HBV and HCV replication. Results showed 90% inhibition of HBV after twenty-four hours and 90-99% inhibition in HCV five days posttreatment.

"We have demonstrated here that replication of HBV and HCV is sensitive to the antiviral activities of interferon lambda," say the researchers. "These results suggest the possibility that interferon lambda may be therapeutically useful in the treatment of chronic HBV or HCV infection."

(M.D. Robek, B.S. Boyd, F.V. Chisari. 2005. Lambda interferon inhibits hepatitis B and C virus replication. Journal of Virology, 79. 6: 3851-3854.)


'"/>

Source:American Society for Microbiology


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. HIV vaccine trial breaks ground for future research
7. Live vaccines more effective against horse herpes virus
8. NIAID begins clinical trial of West Nile virus vaccine
9. Designing vaccines by computer
10. Wake Forest scientists find new combination vaccine effective against plague
11. New vaccine means bye-bye to bacteria in the lung
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Norovirus AIDS vaccine and Hepatitis Virus

(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... a review of the latest clinical trials, coronary artery bypass ... a heart-lung machine, is a safe option that leads to ... featured in Journal of Cardiac Surgery. , “Previously, it ... on the heart by stopping the heart and passing the ...
... Studies in mice have indicated that the effects of ... The researchers said that their findings support developing early ... in the brains of people with prion disease. Also, ... of treatments in a new way: by analyzing their ...
... strongest evidence yet that sudden infant death syndrome (SIDS) is ... In the November 1 issue of JAMA, researchers at Children's ... the brain that regulates breathing, blood pressure, body heat, and ... is the leading cause of death in American infants after ...
Cached Biology News:Prion disease treatable if caught early 2A potential biological cause for sudden infant death syndrome 2A potential biological cause for sudden infant death syndrome 3
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development ... for the quarter ended June 30, 2015, corporate ... and management report are available at www.sedar.com ... . "RepliCel expects to launch ...
(Date:8/28/2015)... ... ... the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake ... as the Fonz in a lab coat and Large Marge have been posted on the ... , FireflySci is proud to be the only cuvette manufacturer is the world that ...
(Date:8/27/2015)... Reston, VA (PRWEB) , ... August 27, 2015 , ... ... government contractors solve complex business problems, is pleased to announce their ranking as one ... 34th annual ranking of the fastest-growing private companies across the nation. , “It is ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... , BRIDGEWATER, N.J., Sept. 14 ... Leader (KOL) relationship management, identification, influence mapping and automated ... momentum in its impact to support expanding customer needs ... vice president and general manager, InsiteResearch, will address two ...
... , SAN DIEGO, Sept. 14 ... new class of naturally occurring proteins as biotherapeutics, will present ... on Friday, September 18th. Jeff Watkins, CEO of aTyr ... engine, and lead program based on naturally occurring resected proteins ...
... JOHNSON CITY, Tenn., Sept. 14 RxBio, Inc., announces that its ... against lethal, whole-body radiation when administered before, during, or up to ... recent experiments, the efficacy of Rx100 was tested by treating with ... lethal, whole-body gamma irradiation. Results at both time points were ...
Cached Biology Technology:InsiteResearch Market Momentum Continues to Accelerate 2InsiteResearch Market Momentum Continues to Accelerate 3aTyr Pharma to Present at BioPharm America 2009 2Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation! 2
WD-repeat protein 4...
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
... Cultured human omental ... obese but otherwise healthy ... availability of diabetic cells. ... information. Support media also ...
ASCIZ...
Biology Products: